EDITAS MEDICINE, INC. Operating Lease Cost
EDITAS MEDICINE, INC. (EDIT) reported Operating Lease Cost of $14.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-09
- EDITAS MEDICINE, INC. operating lease, cost for the quarter ending 2019-12-31 was $1.31M.
- EDITAS MEDICINE, INC. operating lease, cost for the quarter ending 2019-09-30 was $1.45M.
- EDITAS MEDICINE, INC. operating lease, cost for the quarter ending 2019-06-30 was $1.42M.
- EDITAS MEDICINE, INC. operating lease, cost for the quarter ending 2019-03-31 was $1.42M.
- EDITAS MEDICINE, INC. operating lease, cost for fiscal 2025 was $14.80M, a 29.52% decline from fiscal 2024.
- EDITAS MEDICINE, INC. operating lease, cost for fiscal 2024 was $21.00M, a 38.16% increase from fiscal 2023.
- EDITAS MEDICINE, INC. operating lease, cost for fiscal 2023 was $15.20M, a 11.76% increase from fiscal 2022.
- EDITAS MEDICINE, INC. operating lease, cost for fiscal 2022 was $13.60M, a 24.77% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $14.80M 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $21.00M 10-K · filed 2026-03-09 | |||
| 2023-12-31 | $15.20M 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $13.60M 10-K · filed 2025-03-05 | |||
| 2021-12-31 | $10.90M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $10.50M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.76M derived: sum of 2 quarters · filed 2021-02-26 | $4.18M derived: sum of 3 quarters · filed 2021-02-26 | $5.60M 10-K · filed 2021-02-26 |
| 2019-09-30 | $1.45M 10-Q · filed 2019-11-12 | $2.87M derived: sum of 2 quarters · filed 2019-11-12 | $4.29M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.42M 10-Q · filed 2019-08-07 | $2.84M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $1.42M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |